Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | AG-120 and VIDAZA - (AGILE) | Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer | Phase 3 | Trial Completed | Oral and subcutaneous | Oncology |
| Agios Pharmaceuticals Inc. | Mitapivat (AG-348) - (ESTIMATE Open Label) | Sickle Cell Disease | Phase 2 | Ongoing | Oral | Hematology |
| Agios Pharmaceuticals Inc. | AG-946 | Myelodysplastic syndrome (MDS) | Phase 2a | Ongoing | oral | Hematology |
| Agios Pharmaceuticals Inc. | Mitapivat (AG-348) - (RISE UP) | Sickle cell disease | Phase 3 | Data Released | Oral | Hematology |
| Agios Pharmaceuticals Inc. | Mitapivat - (SATISFY) | Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II | Phase 2 | Ongoing | Oral | Hematology |
| Agios Pharmaceuticals Inc. | Mitapivat (AG-348) - (ACTIVATE kids-T study) | Pediatric PK Deficiency | Phase 3 | Data Released | Oral | Genetic Disorder |
| Agios Pharmaceuticals Inc. | TIBSOVO (ivosidenib) - (ClarIDHy) | IDH1 mutant cholangiocarcinoma - cancer | sNDA Filing | Trial Completed | oral | Oncology |
| AIM ImmunoTech Inc. | Ampligen, Intron A, and celecoxib | Colorectal cancer | Phase 2 | Ampligen intravenous Intron A subcutaneous intramuscular intravenous celecoxib oral | Oncology |
